Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell; Kami J. Maddocks; Eva González-Barca; Wojciech Jurczak; Anna Marina Liberati; Sven De Vos; Zsolt Nagy; Aleš Obr; Gianluca GAIDANO; Pau Abrisqueta; Nagesh Kalakonda; Marc André; Martin Dreyling; Tobias Menne; Olivier Tournilhac; Marinela Augustin; Andreas Rosenwald; Maren Dirnberger-Hertweck; Johannes Weirather; Sumeet Ambarkhane; Gilles Salles

doi:10.3324/haematol.2021.279802

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell
, Kami J. Maddocks
, Eva González-Barca
, Wojciech Jurczak
, Anna Marina Liberati
, Sven De Vos
, Zsolt Nagy
, Aleš Obr
, Gianluca GAIDANO
, Pau Abrisqueta
, Nagesh Kalakonda
, Marc André
, Martin Dreyling
, Tobias Menne
, Olivier Tournilhac
, Marinela Augustin
, Andreas Rosenwald
, Maren Dirnberger-Hertweck
, Johannes Weirather
, Sumeet Ambarkhane

Gilles Salles

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

: Not available.

Lingua originale	Inglese
Rivista	Haematologica
DOI	https://doi.org/10.3324/haematol.2021.279802
Stato di pubblicazione	Pubblicato - 1 gen 0001

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.3324/haematol.2021.279802

http://hdl.handle.net/11579/138284

Altri file e collegamenti

handle

Cita questo

Duell, J., Maddocks, K. J., González-Barca, E., Jurczak, W., Liberati, A. M., De Vos, S., Nagy, Z., Obr, A., GAIDANO, G., Abrisqueta, P., Kalakonda, N., André, M., Dreyling, M., Menne, T., Tournilhac, O., Augustin, M., Rosenwald, A., Dirnberger-Hertweck, M., Weirather, J., ... Salles, G. (1). Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. https://doi.org/10.3324/haematol.2021.279802

@article{fc55ea727ac04bda85e1547db246f978,

title = "Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma",

abstract = ": Not available.",

author = "Johannes Duell and Maddocks, \{Kami J.\} and Eva Gonz{\'a}lez-Barca and Wojciech Jurczak and Liberati, \{Anna Marina\} and \{De Vos\}, Sven and Zsolt Nagy and Ale{\v s} Obr and Gianluca GAIDANO and Pau Abrisqueta and Nagesh Kalakonda and Marc Andr{\'e} and Martin Dreyling and Tobias Menne and Olivier Tournilhac and Marinela Augustin and Andreas Rosenwald and Maren Dirnberger-Hertweck and Johannes Weirather and Sumeet Ambarkhane and Gilles Salles",

year = "1",

month = jan,

day = "1",

doi = "10.3324/haematol.2021.279802",

language = "English",

journal = "Haematologica",

issn = "1592-8721",

publisher = "Ferrata Storti Foundation",

}

Duell, J, Maddocks, KJ, González-Barca, E, Jurczak, W, Liberati, AM, De Vos, S, Nagy, Z, Obr, A, GAIDANO, G, Abrisqueta, P, Kalakonda, N, André, M, Dreyling, M, Menne, T, Tournilhac, O, Augustin, M, Rosenwald, A, Dirnberger-Hertweck, M, Weirather, J, Ambarkhane, S & Salles, G 1, 'Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma', Haematologica. https://doi.org/10.3324/haematol.2021.279802

TY - JOUR

T1 - Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

AU - Duell, Johannes

AU - Maddocks, Kami J.

AU - González-Barca, Eva

AU - Jurczak, Wojciech

AU - Liberati, Anna Marina

AU - De Vos, Sven

AU - Nagy, Zsolt

AU - Obr, Aleš

AU - GAIDANO, Gianluca

AU - Abrisqueta, Pau

AU - Kalakonda, Nagesh

AU - André, Marc

AU - Dreyling, Martin

AU - Menne, Tobias

AU - Tournilhac, Olivier

AU - Augustin, Marinela

AU - Rosenwald, Andreas

AU - Dirnberger-Hertweck, Maren

AU - Weirather, Johannes

AU - Ambarkhane, Sumeet

AU - Salles, Gilles

PY - 1/1/1

Y1 - 1/1/1

N2 - : Not available.

AB - : Not available.

UR - https://iris.uniupo.it/handle/11579/138284

U2 - 10.3324/haematol.2021.279802

DO - 10.3324/haematol.2021.279802

M3 - Article

SN - 1592-8721

JO - Haematologica

JF - Haematologica

ER -

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo